Cargando…
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib
BACKGROUND: Patients with immune thrombocytopenia (ITP) are at risk of bleeding and, paradoxically, thromboembolic events (TEEs), irrespective of thrombocytopenia. The risk of thrombosis is increased by advanced age, obesity, and prothrombotic comorbidities: cancer, hyperlipidemia, diabetes, hyperte...
Autores principales: | Cooper, Nichola, Altomare, Ivy, Thomas, Mark R., Nicolson, Phillip L. R., Watson, Steve P., Markovtsov, Vadim, Todd, Leslie K., Masuda, Esteban, Bussel, James B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111531/ https://www.ncbi.nlm.nih.gov/pubmed/33995988 http://dx.doi.org/10.1177/20406207211010875 |
Ejemplares similares
-
Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020) -
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials
por: Bussel, James, et al.
Publicado: (2018) -
Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
por: Bussel, James B., et al.
Publicado: (2019) -
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
por: Harbi, Maan H., et al.
Publicado: (2022) -
88. Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial
por: Gotur, Deepa B, et al.
Publicado: (2023)